Dr. Kudrik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
166 Stoneridge Dr
Columbia, SC 29210Phone+1 803-461-3000Fax+1 803-461-4910
Summary
- President of S.C. Oncology Associates
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2000 - 2002
University of RochesterResidency, Internal Medicine, 1997 - 2000
Case Western Reserve University School of MedicineClass of 1997
Certifications & Licensure
SC State Medical License 2002 - 2025
NC State Medical License 1999 - 2002
NY State Medical License 1998 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Publications & Presentations
PubMed
- 10 citationsThe burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA).John F. Reitan, Fred J. Kudrik, Kayleen Fox, Arletta van Breda, Sanatan Shreay
Journal of Medical Economics. 2013-02-21 - 56 citationsPhase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Pat...Mark A. Socinski, Frederic J. Kaye, David R. Spigel, Fred J. Kudrik, Santiago Ponce
Clinical Lung Cancer. 2017-01-01 - 116 citationsA Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adeno...Al B. Benson, Zev A. Wainberg, J. Randolph Hecht, Dmitry Vyushkov, Hua Dong
The Oncologist. 2017-03-01
Press Mentions
Integra Connect to Present Key Clinical Research at the ASCO Quality Care SymposiumOctober 26th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
